R
Richard W. Joseph
Researcher at Mayo Clinic
Publications - 153
Citations - 19206
Richard W. Joseph is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Pembrolizumab & Melanoma. The author has an hindex of 40, co-authored 153 publications receiving 15419 citations. Previous affiliations of Richard W. Joseph include University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Omid Hamid,Caroline Robert,Adil Daud,F. Stephen Hodi,Wen-Jen Hwu,Richard F. Kefford,Jedd D. Wolchok,Peter Hersey,Richard W. Joseph,Jeffrey S. Weber,Roxana S. Dronca,Tara C. Gangadhar,Amita Patnaik,Hassane M. Zarour,Anthony M. Joshua,Kevin Gergich,Jeroen Elassaiss-Schaap,Alain Algazi,Christine Mateus,Peter D. Boasberg,Paul C. Tumeh,Bartosz Chmielowski,Scot Ebbinghaus,Xiaoyun Nicole Li,S. Peter Kang,Antoni Ribas +25 more
TL;DR: In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects.
Journal ArticleDOI
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg,Jean H. Hoffman-Censits,Thomas Powles,Michiel S. van der Heijden,Arjun Vasant Balar,Andrea Necchi,Nancy A. Dawson,Peter H. O'Donnell,Ani Balmanoukian,Yohann Loriot,Sandy Srinivas,Margitta Retz,Petros Grivas,Richard W. Joseph,Matthew D. Galsky,Mark D. Fleming,Daniel P. Petrylak,Jose Luis Perez-Gracia,Howard A. Burris,Daniel Castellano,Christina Canil,Joaquim Bellmunt,Dean F. Bajorin,Dorothee Nickles,Richard Bourgon,Garrett M. Frampton,Na Cui,Sanjeev Mariathasan,Oyewale O. Abidoye,Gregg Fine,Robert Dreicer +30 more
TL;DR: Treatment with atezolizumab resulted in a significantly improved RECIST v1.1 response rate, compared with a historical control overall response rate of 10%, and Exploratory analyses showed The Cancer Genome Atlas (TCGA) subtypes and mutation load to be independently predictive for response to atezolediazepine.
Journal ArticleDOI
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Arjun Vasant Balar,Matthew D. Galsky,Jonathan E. Rosenberg,Thomas Powles,Daniel P. Petrylak,Joaquim Bellmunt,Yohann Loriot,Andrea Necchi,Jean H. Hoffman-Censits,Jose Luis Perez-Gracia,Nancy A. Dawson,Michiel S. van der Heijden,Robert Dreicer,Sandy Srinivas,Margitta Retz,Richard W. Joseph,Alexandra Drakaki,Ulka N. Vaishampayan,Srikala S. Sridhar,David I. Quinn,Ignacio Duran,David R. Shaffer,Bernhard J. Eigl,Petros Grivas,Evan Y. Yu,S. Li,Edward E. Kadel,Zachary Boyd,Richard Bourgon,Priti S. Hegde,Sanjeev Mariathasan,Ann Christine Thastrom,Oyewale O. Abidoye,Gregg Fine,Dean F. Bajorin +34 more
TL;DR: Atezolizumab showed encouraging durable response rates, survival, and tolerability, supporting its therapeutic use in untreated metastatic urothelial cancer.
Journal ArticleDOI
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial
Caroline Robert,Antoni Ribas,Jedd D. Wolchok,F. Stephen Hodi,Omid Hamid,Richard F. Kefford,Richard F. Kefford,Jeffrey S. Weber,Anthony M. Joshua,Wen-Jen Hwu,Tara C. Gangadhar,Amita Patnaik,Roxana S. Dronca,Hassane M. Zarour,Richard W. Joseph,Peter D. Boasberg,Bartosz Chmielowski,Christine Mateus,Michael A. Postow,Kevin Gergich,Jeroen Elassaiss-Schaap,Xiaoyun Nicole Li,Robert Iannone,Scot Ebbinghaus,S. Peter Kang,Adil Daud +25 more
TL;DR: The results suggest that pembrolizumab at a dose of 2mg/kg or 10 mg/kg every 3 weeks might be an effective treatment in patients for whom there are few effective treatment options.
Journal ArticleDOI
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott,Mahrukh Huseni,Michael B. Atkins,Robert J. Motzer,Brian I. Rini,Bernard Escudier,Lawrence Fong,Richard W. Joseph,Sumanta K. Pal,James A. Reeves,Mario Sznol,John D. Hainsworth,W. Kimryn Rathmell,Walter M. Stadler,Thomas E. Hutson,Martin Gore,Alain Ravaud,Sergio Bracarda,Cristina Suarez,Riccardo Danielli,Viktor Gruenwald,Toni K. Choueiri,Dorothee Nickles,Suchit Jhunjhunwala,Elisabeth Piault-Louis,Alpa Thobhani,Jiaheng Qiu,Daniel S. Chen,Priti S. Hegde,Christina Schiff,Gregg Fine,Thomas Powles +31 more
TL;DR: Molecular profiles suggest that prediction of outcomes with anti-VEGF and immunotherapy may be possible and offer mechanistic insights into how blocking VEGF may overcome resistance to immune checkpoint blockade.